Johnson & Johnson Announces Phase III Data Showing Icotrokinra Outperforms BMS’s Deucravacitinib in Plaque Psoriasis

Local time on September 17, Johnson & Johnson announcedWorld's First Oral Targeted IL-23R PeptideIcotrokinra Head-to-Head deucravacitinib（Deucravacitinib, Trade Name:Sotyktu）TheTwo Phase IIIICONIC-ADVANCE 1 and 2 Study Data。

The results showed,Icotrokinra is superior toDeucravacitinib, further demonstrating the promising prospects of novel targeted oral peptide therapy for plaque psoriasis.。

Source: Johnson & Johnson Official Website

ICONIC-ADVANCE 1 and 2 are randomized controlled Phase III clinical trials designed to evaluateIcotrokinra andDeucravacitinib and AnCompared with placebo, the efficacy and safety in patients with moderate to severe plaque psoriasis. The co-primary endpoints are the subjects achieving PASI 90 (90% improvement in Psoriasis Area and Severity Index)AndIGA score is 0/1(Skin symptoms eliminated or nearly eliminated), and improve by at least 2 grades.

In these two studies,Icotrokinra achieved two co-primary endpoints at Week 16 compared to placebo.The incidence of adverse events was similar. , and at the time point, it demonstrated superior efficacy and safety compared to deucravacitinib.

• Compared with placebo(Week 16)AndDeucravacitinib(Week 16 and Week 24)In comparison,Icotrokinra Shows Superior Skin Clearance Rate。
  

• Adverse Events of Icotrokinra (AE) The incidence rate was similar to that of the placebo, and no new safety signals were identified. As of Week 24,Week, the AE incidence rate of Icotrokinra was numerically lower thanDeucravacitinib。

Johnson & Johnson has also launched the Phase III ICONIC-ASCEND study, which is the firstHead-to-Head Ustekinumab Phase III Clinical Trial。

In terms of long-term data, in the ICONIC-LEAD study,Icotrokinra Demonstrates Sustained Skin Clearance and Favorable Safety in Adult and Adolescent Patients at Week 52。

• At Week 52, adult patients who achieved PASI 90 and were re-randomized to the icotrokinra group at Week 24 had a higher PASI 90 maintenance rate compared to those re-randomized to the placebo group.（84% vs 21%；p<0.001）。
• At week 52, 86% of adolescents treated with icotrokinra for 52 weeks achieved PASI 90, while 77% of those who switched from placebo to icotrokinra at week 16 achieved PASI 90.

Icotrokinra isJohnson & Johnson, which invested nearly $1 billion to acquire the world's first oral IL-23R antagonist from Protagonist, submitted it for marketing approval in the U.S. this July and in Europe this September. Johnson & Johnson predicts that the sales peak of icotrokinra may reach $7.5 billion.

DeucravacitinibIt is a TYK2 inhibitor,Approved for marketing in the U.S. in September 2022 for adult plaque psoriasis, becoming the world's first approved TYK-2 allosteric inhibitor. In 2024, the drug's global sales reached $246 million, a significant year-over-year increase of 44.71%.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb